ClinicalTrials.gg
CompletedNCT02959476Updated Aug 14, 2018

Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

A Phase 3 interventional study of Ropivacaine and Placebos in Pain, Postoperative, sponsored by BioQ Pharma, Inc.. Completed at 11 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2018-08-14.

Sponsored by BioQ Pharma, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.

Enrollment
27th of 184
132 · median 70
Started
2017
with 14 others
Phase 3
23 of 184
none open now
Registered
83rd of 184
by date

Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 27th largest by enrollment, is one of 15 that started in 2017, is one of 23 in phase 3, and was the 83rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies testing ropivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This study evaluates a Ropivacaine 0.2% Pre-Filled Dispenser in the treatment of post-surgical pain in patients undergoing Cesarean delivery. Half of the patients will receive Ropivicaine and half will receive placebo.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • Postoperative pain
  • Postsurgical pain
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Complete the process as documented by a signed informed consent form (ICF).
  • Be in generally good health and classified as either PS-1 or PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
  • Have a single birth pregnancy. Can be parous or nulliparous.
  • Be scheduled for a Cesarean Delivery
  • Subjects undergoing emergency Cesarean Delivery will not be eligible for participation in this study.
  • In the event a subject signs the ICF (but has not been randomized), has a C section planned and then has an emergency C section delivery, this subject will be considered a screen failure.
  • In the unlikely event a subject signs the ICF and is randomized into the study, has a C section planned and then has an emergency C section delivery, this subject will continue in the study as planned.
  • Be willing to complete the pain assessments according to the protocol and return to clinic as scheduled, as needed.

Exclusion criteria

Exclusion Criteria:

  • Have an uncontrolled medical condition, serious intercurrent illness, general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.
  • Have a clinically significant abnormal (ECG) at screening as determined by the Investigator.
  • Have a history of any medical condition or surgical procedure that would alter the absorption, distribution, metabolism, or excretion of ropivacaine.
  • Have, in the opinion of the investigator, a clinically significant abnormality in their clinical laboratory values (urinalysis, hematology and chemistry) at screening.
  • Have made a donation (standard donation amount or more) of blood or blood products (with the exception of plasma as noted below) within 56 days prior to Day 1.
  • Weigh greater than 100 kg (220 lbs).
  • Have made a plasma donation within 7 days prior to Day -1.
  • Have a known allergy or to anesthetics (eg. Ropivacaine), acetaminophen, or non-steroidal anti inflammatory drugs (NSAIDs, eg, ibuprofen or naproxen, ketorolac).
  • Not be able or willing to discontinue the prohibited medications listed below within the allotted time before surgery and throughout the duration of their participation in the study.

    • monoamine oxidase inhibitors (MAOIs) within the past 30 days
    • anticonvulsants, tricyclic antidepressants (TCAs), neuroleptics, serotonin-norepinephrine reuptake inhibitors (SNRIs), as well as selective serotonin reuptake inhibitors (SSRIs) (unless SSRIs have been prescribed for depression and/or anxiety and subjects have been on a stable dose for at least 30 days prior to the screening visit);
    • : Oral and injectable corticosteroids must be discontinued 3 months prior to surgery; nasal, inhaled and topical corticosteroids will be allowed;
  • Use concurrent therapy that could interfere with the evaluation of efficacy or safety parameters in the opinion of the investigator (eg, any drugs, in the investigator's opinion, that may exert significant analgesic properties), except for rescue medications.
  • Have a history of seizures or history of serious head injury.
  • Must not be a member of a vulnerable population as defined by the Code of Federal Regulations Title 45, Part 46, Delivery 46.111(b), including but not limited to employees (temporary, part-time, full-time, etc.) or a family member of the research staff conducting the study, or of the Sponsor, or of the Clinical Research Organization.
  • Have previously participated in a clinical trial using ropivacaine.
  • Have a history of major mental illness that in the opinion of the Investigator may affect the ability of the subject to participate in the study. Institutionalized subjects will not be eligible for participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Ropivacaine 0.2%

    Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - "Ropivacaine Infusion treatment arm"

    Drug: Ropivacaine

  • Placebo comparator
    Placebo

    Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - "Placebo treatment arm"

    Drug: Placebos

Interventions

  • Anesthetic

  • DrugPlacebos

    Inactive comparator

06

What researchers measure

Primary outcomes

  1. Cumulative analgesic effect

    Time frame: 48 hours

Secondary outcomes

  1. Use of other analgesics

    Time frame: 48 hours

  2. Local safety and tolerability using descriptive statistics of the evaluation of physical exams, wound healing and treatment-emergent adverse events local to the surgical wound

    Time frame: 7 days

  3. Overall safety using descriptive statistics of the evaluation of physical exam, vital signs, clinical laboratory tests, and treatment-emergent adverse events

    Time frame: 7 days

  4. Analgesic effect at specified intervals

    Time frame: 48 hours

07

Study locations

11 sites
  • Clinical Research Associates, Inc.
    Birmingham, Alabama 35205, United States
  • Shoals Medical Trials, Inc.
    Sheffield, Alabama 35660, United States
  • University of California, Irvine
    Orange, California 92868, United States
  • Vision Clinical Research
    Wellington, Florida 33414, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • MedPharmics, LLC
    Biloxi, Mississippi 39531, United States
  • Duke University Medical Center
    Durham, North Carolina 27606, United States
  • Compass Clinical Trial
    Beaumont, Texas 77702, United States
  • Physician's Research Options, LLC- Corner Canyon OB/GYN
    Draper, Utah 84020, United States
  • Health Sciences Center- University of Utah
    Salt Lake City, Utah 84112, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Aug 2018, 16 months.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 16 months is above that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2016
First posted
Nov 9, 2016
StartActual
Mar 13, 2017
Primary completionActual
Aug 10, 2018
CompletionActual
Aug 10, 2018
Last update
Aug 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02959476
Lead sponsor
BioQ Pharma, Inc.
Collaborators
Health Decisions
Responsible party
Sponsor
First posted
Nov 9, 2016
Start date
Mar 13, 2017
Primary completion
Aug 10, 2018
Completion
Aug 10, 2018
Last update
Aug 14, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion